Iron storage within dopamine neurovesicles revealed by chemical nano-imaging

PLoS ONE

Volumn 2, Issue 9, 2007, Pages

  Ortega, Richard ^a   Cloetens, Peter ^b   Devès, Guillaume ^a   Carmona, Asunción ^c   Bohic, Sylvain ^d  

^a CENTRE D ETUDES NUCLÉAIRES DE BORDEAUX GRADIGNAN   (France)

^b EUROPEAN SYNCHROTRON RADIATION FACILITY   (France)

^c CENTRO NACIONAL DE ACELERADORES   (Spain)

^d GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; IRON; METIROSINE; POTASSIUM; TYROSINE 3 MONOOXYGENASE; ZINC;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BRIGHTNESS; CELL COMPARTMENTALIZATION; CELL STRAIN; CELL TRANSPORT; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINE METABOLISM; HOMEOSTASIS; IRON STORAGE; NANOIMAGING; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; SYNCHROTRON; X RAY FLUORESCENCE; ANIMAL; CYTOLOGY; CYTOPLASM VESICLE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE; FLUORESCENCE MICROSCOPY; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; SPECTROMETRY;

ALPHA-METHYLTYROSINE; ANIMALS; CYTOPLASMIC VESICLES; DOPAMINE; FLUORESCENCE; IRON; MICROSCOPY, FLUORESCENCE; NANOTECHNOLOGY; NEURONS; PC12 CELLS; POTASSIUM; RATS; SPECTROMETRY, X-RAY EMISSION; TYROSINE 3-MONOOXYGENASE; ZINC;

EID: 41749083754     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000925     Document Type: Article

References (35)

1. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways in neurodegeneration. Nature Med 10: S2-S9.
2. Gaeta A, Hider RG (2005) The crucial role of metal ions neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146: 1041-1059.
3. Ke Y, Ming Qan Z (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2: 246-56.
4. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nature Rev Neurosci 5: 863-873.
5. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, et al. (1987) Increased nigral iron content in post-mortem parkinsonian brain. Lance 2: 1219-1220.
6. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, et al. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520.
7. Griffiths PD, Dobson BR, Jones GR, Clarke DT (1999) Iron in the basal ganglia in Parkinson's disease: an in vitro study using extended X-ray absorption fine strucutre and cryo-electron microscopy. Brain 122: 667-673.
8. Ben Shachar B, Kahana N, Kampel V, Warshawsky A, Youdim MBH (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacol 46: 254-263.
9. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, et al. (2003) Genetic or pharmacologic iron chelation prevents MPTP-induced neurotoxicity in vivo. A novel therapy for Parkinson's disease. Neuron 37: 899-909.
10. Linert W, Jameson GNL (2000) Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. J Inorg Biochem 79: 319-326.
11. Paris I, Martinez-Alvarado P, Cardenas S, Pelrez-Pastene C, Graumann R (2005) Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 18: 415-419.
12. Smythies J (1999) The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. Neurotox Res 1: 27-39.
13. Ortega R, Bohic S, Tucoulou R, Somogyi A, Devès G (2004) Microchemical element imaging of yeast and human cells using synchrotron x-ray microprobe with Kirkpatrick-Baez optics. Anal Chem 76: 309-314.
14. Greene Li, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Nad Acad Sci USA 73: 2424-2428.
15. Tischler AS, Greene LA (1978) Morphologic and cytochemical properties of a clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Lab Invest 39: 77-89.
16. Falck B, Hillarp NA, Thieme G, Torp A (1962) Fluorescence of catcchol amines and related compounds condensed with formaldhehyde. J Histochem Cytocbem 10: 348-354.
17. Clarke SJ, Hollmann CA, Zhang Z, Suffern D, Bradforth SE et al (2006) Photophysics of dopamine-modified quantum dots and effects on biological systems. Nature Mat 5: 409-418.
18. Liu Y, Schweitzer ES, Nirenberg MJ, Pickel VM, Evans CJ et al (1994) Preferential localization of a vesicular monoaminc transporter to dense core vesicles in PC12 cells. J Cell Biol 127: 1419-1433.
19. Zierold K, Schafer D, Pietruschka F (1984) The element distribution in ultrathin cryosections of cultivated fibroblast cells. Histochem 80: 333-337.
20. Ortega R, Moretto P, Fajac A, Bénard J, Llabador Y, et al. (1996) Quantitative mapping of platinmu and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. Cell Mol Biol 42: 77-88.
21. Eide DJ (2006) Zinc transporters and the cellular trafficking of zinc. Biochim Biophys Acts, 1763: 711-722.
22. Galvani P, Colleoni M, Origgi M, Santagostino A (1995) Mitochondrial toxicity of iron and the protective role of ferritin on dopaminergic PC12 cells Toxicol In Vitro 9: 365-368.
23. Reaney SH, Smith DR (2005) Manganese oxidation state mediates toxicity in PC12 cells. Toxicol Appl Pharmacol 205: 271-281.
24. Quintana C, Bellefqih S, Laval JY, Guerquin-Kern JL, Wu TD, et al. (2006) Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 153: 42-54.
25. Zhang P, Land W, Lee S, Juliani J, Lefman J, et al. (2005) Electron tomography of degenerating neurons in mice with abnormal regulation of iron metabolism. J Struct Biol 150: 144-153.
26. Rouault TA (2001) Iron on the brain. Naturr Genetics 28: 299-300.
27. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345-348.
28. Kastner A, Hirsch EC, Agid Y, Javoy-Agid F (1993) Tyrosinc hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res 606: 341-345.
29. Mori F. Nishie M, Kakita A. Yoshimoto M, Takahashi H. et al. (2006) Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia, nigra. J Neuropathol Exp Neurol 65: 808-815.
30. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease, dopamine, vesicles, and α-synuclein. Nature Rev Neurosci 3: 932-942.
31. Lashuel HA, Hirling H (2006) Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease. ACS Chem Biol 1: 420-4.
32. Hignette O, Cloetens P, Rostaing G, Bernard P, Morawe C (2005) Efficient sub 100 nm focusing of hard x rays. Rev Sci Instrum 76: 063709.
33. Kirkpatrick P, Baez AV (1948) Formation of optical images by X-rays. J Opt Soc Am 38: 766-774.
34. Bohic S, Simionovici A, Ortega R, Heymann D, Schroer C, et al. (2001) Synchrotron hard X-ray microprobe: fluorescence imaging of single cells. AppI Phys Letters 78: 3544-3546.
35. Solé VA, Papillon E, Cotte M, Walter Ph, Susini J (2007) A multiplatform code for the analysis of energy-dispersive X-ray fluorescence spectra. Spectrochim Acta. B62: 63-68.